ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor - Wikidata - thesis-toulmin - TriplyDB

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

http://www.wikidata.org/entity/Q29616727

about

Novel agents for chronic lymphocytic leukemia Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4 Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy Small-molecule Bcl-2 antagonists as targeted therapy in oncology Mitochondria, cholesterol and cancer cell metabolism Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies Update on rational targeted therapy in AML Current challenges and novel treatment strategies in double hit lymphomas Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics Regulation of Bim in Health and Disease Treatment Strategies that Enhance the Efficacy and Selectivity of Mitochondria-Targeted Anticancer Agents Bcl-2 antagonists: a proof of concept for CLL therapy Chloroquine and hydroxychloroquine for cancer therapy Targeting BCL2-Proteins for the Treatment of Solid Tumours Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics Novel agents in mantle cell lymphoma How cell death shapes cancer Targeting the apoptosis pathway in hematologic malignancies Getting TRAIL back on track for cancer therapy Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Dynamics of Bcl-xL in water and membrane: molecular simulations Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition Mito-priming as a method to engineer Bcl-2 addiction.BAX activation is initiated at a novel interaction site Conformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind Ligands Mcl-1-Bim complexes accommodate surprising point mutations via minor structural changes Determinants of BH3 Binding Specificity for Mcl-1 versus Bcl-xL The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer Discovery and molecular characterization of a Bcl-2-regulated cell death pathway in schistosomes Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design Experimental and computational active site mapping as a starting point to fragment-based lead discovery Structure-function analyses of the human SIX1–EYA2 complex reveal insights into metastasis and BOR syndrome Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold Structure-Guided Rational Design of α/β-Peptide Foldamers with High Affinity for BCL-2 Family Prosurvival Proteins

P2860

Q21198858-5245A162-CF20-4875-B39D-B3BB374F117C Q24294703-07F1B2D2-4278-4188-BA9B-C1A61857EE6C Q24298561-E733F15F-C20F-4C7B-8E48-B96E232E49D4 Q24306326-C61A7014-2DAC-4935-97AC-3B8886A91CD7 Q24312998-E801589B-C385-45C7-A153-BA225CAA6FF1 Q24315549-C359E530-E398-4DA4-9AB6-B5BEC768687B Q24337757-17246B8D-1A5F-4526-9730-729D0F33C636 Q24635408-263B9998-30ED-437D-AA78-3A22EC558BD8 Q24646161-84C4F6FC-3F0A-4473-8B22-017BA9A2673F Q26741708-B3E711EE-E5CE-4AF3-9ED1-55ADCF357187 Q26750639-3C51AE3D-A1BE-4EEA-8462-80AF963C846B Q26766152-15900429-4E8D-4CE2-BD9B-AD1BCD4B4573 Q26770385-C6165928-100F-4327-A5C8-1218B954E1F0 Q26775356-559C3C11-B00B-4A7B-95BB-9DBC17039123 Q26781203-07C9C62B-81F9-4668-9F78-27300F467ABE Q26800890-9D31DC4F-EF11-41B0-BD93-6887C977DCE6 Q26823996-4B53356B-94BC-44AD-AA65-F0F1E9924DD5 Q26827797-47851720-D9DC-4967-BA24-BDB707D8D724 Q26853686-A8D52214-54D2-4A05-8B72-81CC8B9F6894 Q27001269-60176950-6C2E-4806-9DF3-F0A9A759CD72 Q27010154-FB35D2C9-AB9A-44CE-BA5F-BEDE53D3B1F5 Q27011763-0536E48D-CFD4-4EA2-BA09-C82D46A16B38 Q27021441-29B8F9B1-9215-4458-99AC-0D35EAC772F5 Q27024422-59C2D629-2491-4E47-842D-CA93917F0443 Q27027460-CDA0FADC-8C2F-4106-A6E4-4F2010961740 Q27304386-EA92E305-71FD-43AD-B91F-FF73B447C9AD Q27304496-8CFFE0FA-9F0D-4656-88FA-9E8203FD0C0B Q27330047-86E6D420-D155-40F5-BC0C-11D874D5A1EB Q27334195-9281D21E-BF6C-4E9B-8CDF-46C748547921 Q27652635-BED9AE2B-A8A3-4291-9B99-DBFF7DDE1931 Q27657282-C9A3AD63-5C6F-40CB-A4A6-356034D253EC Q27658925-62BBE249-3685-4DF2-83A2-979CCC7ED2BB Q27660407-91C6D0E3-1251-4E6D-952C-BC5D1345EE6E Q27662487-BE1FDD75-934A-4938-B083-4DBA928C0FFB Q27667342-E23574E9-AC14-458C-ACC0-7C538EDFC932 Q27675512-A40608C4-2DDF-4B35-B4C8-166B2AC05169 Q27676521-B3E676CD-E5D4-43A5-BD97-BCC2B1828E41 Q27676610-36FE6217-6E2E-4953-A500-2B53A5234B9C Q27678209-50CBF4CE-B02F-4628-BA46-A16CA5B7C56C Q27679468-61183DE9-31C9-4F42-AB34-D090A7D5D7A9

P2860

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

http://www.wikidata.org/entity/Q29616727

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

@ast

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

@en

type

label

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

@ast

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

@en

prefLabel

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

@ast

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

@en

P1433

Q29616727-40BC5D48-0493-4F9C-AFF7-B2E7CBA81871

P1476

Q29616727-B6842C8B-E003-4B6C-8586-C349AC4D6249

P2093

Q29616727-11148E0D-A9EF-452A-ABC1-E4A716C5395B

Q29616727-23160D92-494C-4D20-B8C1-575BC4D7D833

Q29616727-3718538F-A0C4-4782-9904-67957C3BA191

Q29616727-3A77A7EB-CDE8-4585-96AB-F30A07135A87

Q29616727-4725BC22-6834-4080-860D-F168E6E343D6

Q29616727-70380C70-F312-49EA-94CA-FEB4D3D5A37E

Q29616727-73DECE0E-BC10-4D8F-BD72-82FBF7188CAC

Q29616727-74521161-A9CD-4B64-A87F-376BFEE24AE2

Q29616727-7F286EA2-82ED-41E3-B803-F92C82D562AF

Q29616727-7F2BE9CF-5072-4A46-BABA-CF6A4C5514CD

P304

Q29616727-D466B49E-1BD9-4F40-909F-73B8B0970D67

P31

Q29616727-3B586C8A-3476-4D68-9236-9A6E76700708

P3181

Q29616727-72CD8D30-69A1-477D-AFC0-9A0F58EBA8A3

P356

Q29616727-12E42F11-1F22-48B8-BEBF-E90D71CF6320

P407

Q29616727-5C7A51B4-66EA-45B8-B09C-1FB8F1A2C3DD

P433

Q29616727-B8F2B42C-8130-4CFF-B80B-895BFAA4D23E

P478

Q29616727-501C52CF-8D6E-44AA-9948-7CE1BC74EA70

P577

Q29616727-32C61F95-B7B0-4149-BCE0-5830686B9345

P698

Q29616727-17213B6A-307E-4A04-8049-3A3AAEB706CD

P3181

P356

0008-5472.CAN-07-5836

P1433

Cancer Research

P1476

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

@en

P2093

Adickes J

http://www.w3.org/2001/XMLSchema#string

Anderson MG

http://www.w3.org/2001/XMLSchema#string

Chen J

http://www.w3.org/2001/XMLSchema#string

Elmore SW

http://www.w3.org/2001/XMLSchema#string

Fesik S

http://www.w3.org/2001/XMLSchema#string

Jin S

http://www.w3.org/2001/XMLSchema#string

Johnson EF

http://www.w3.org/2001/XMLSchema#string

Marsh KC

http://www.w3.org/2001/XMLSchema#string

Mitten MJ

http://www.w3.org/2001/XMLSchema#string

Nimmer P

http://www.w3.org/2001/XMLSchema#string

P304

3421-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1226508

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-07-5836

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18451170

http://www.w3.org/2001/XMLSchema#string